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Abstract The influence of aniso-osmolarity on the activity of 
the MAP kinases Erk-1 and Erk-2 was studied in C6 glioma 
cells. Hypo-osmotic treatment (205 mosinol/l) led to an increased 
activity of Erk-1 and Erk-2 within 3 min, which became maximal 
at 10 min and returned to basal level within 120 min. In contrast, 
Erk activity was reduced under hyper-osmotic conditions (405 
mosmol/1), compared to the normo-osmotic control (305 mosmol/ 
1). Erk activation was accompanied by a mobility shift of Raf-1. 
Hypo-osmotic exposure increased the cytosolic Ca2+ concentra-
tion (|Ca2+]i). Absence of extracellular Ca2+ largely abolished 
the ICa2+]i response to hypo-osmolarity, whereas Erk activation 
following hypo-osmotic stimulation remained unaffected, sug-
gesting a Ca2+ independence of the osmosignalling pathway to 
the MAP kinases. Both the Ca2+ response as well as the Erk 
activation following hypo-osmotic exposure were maintained in 
the presence of the phospholipase C inhibitor U73122. Applica-
tion of 8-CPT cAMP, forskolin/isobutylmethylxanthine or 
isoproterenol blocked Erk activation following hypo-osmotic 
treatment of the cells, suggesting a role of the Ras/Raf pathway 
upstream from Erk-1 and Erk-2. Protein kinase C (PKC) is 
unlikely to play a role in the hypo-osmolarity- induced signalling 
towards MAP kinases, as revealed by inhibition of PKC with 
G66850. Inhibition of pertussis- or cholera toxin-sensitive G-
proteins as well as inhibition of tyrosine kinases with genistein 
and of PI3 kinase by wortmannin had no effect on the Erk 
response to hypo-osmolarity. It is concluded that osmosignalling 
in Co glioma cells differs upstream of the MAP kinases from 
that observed in primary rat astrocytes, H4IIE rat hepatoma 
cells and isolated rat hepatocytes. 
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1. Introduction 
Changes of astrocyte volume are an early event in numer-
ous pathological states such as brain ischemia, hyper-/hypo-
natremia and hepatic encephalopathy (for review, see [1]). Cell 
volume alterations induced by either aniso-osmotic environ-
ments or under the influence of hormones or cumulative sub-
strate accumulation represent an independent signal which 
modulates cell function for example via changes in cyto 
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skeleton, metabolic activities, protein phosphorylation and 
gene expression (for review see [2,3]). Astrocyte swelling was 
shown to stimulate glycogen synthesis [4] and was suggested 
to be a signal for proliferation and thus to play a role in 
gliosis [5]. In F98 glioma cells osmolarity affects the intracel-
lular nucleoside triphosphate level, the rate of fatty acid bio-
synthesis and cytoplasmic pH [6]. Glutathione depletion due 
to diminished synthesis under hypo-natremic conditions was 
reported for C6 glioma cells [7]. In C6 glioma cells hypo-
osmolarity-induced regulatory volume decrease (RVD) occurs 
by loss of KC1 [8,6] and organic osmolytes due to an opening 
of volume-sensitive organic anion channels [9]. Hyper-osmo-
larity-induced regulatory volume increase (RVI) is initially 
performed by ionic mechanisms and a subsequent increase 
of «jyo-inositol transporter mRNA expression [10,11]. 
Hypo-osmotic astrocyte swelling leads to a biphasic re-
sponse of the cytosolic free Ca2+ concentration [Ca2+]j 
[12,13] and a calcium-mediated activation of the MAP kinases 
Erk-1 and Erk-2 [12]. Little is known about osmosignalling in 
glioma cells, which are often used as a model system for 
astrocytes. RVD of hypo-osmotically swollen C6 glioma cells 
was suggested to depend on the action of protein phosphatase 
type 1 and the presence of extracellular Ca2+, although in 
suspensions of fura-2-loaded C6 glioma cells no increase in 
[Ca2+]i following hypo-osmotic swelling was observed [6]. 
The extracellular signal-regulated kinases Erk-1 and Erk-2 
belong to the family of mitogen-activated protein (MAP) ki-
nases, which are central components of the growth factor-in-
duced signal transduction via protein phosphorylation to-
wards nuclear and cytoplasmic targets including 
transcription factors, cytoskeletal proteins and regulatory en-
zymes of protein and glycogen metabolism (reviewed in [14]). 
MAP kinases are activated by phosphorylation on Thr-183 
and Tyr-185 by dual specificity MAP kinase kinases (MEK) 
[15]. The Ras/Raf pathway towards MEK shows sensitivity to 
activators of protein kinase A (PKA) [16-18]. Dual specificity 
MAP kinase phosphatases are able to inactivate the MAP 
kinases [19]. 
The present study shows aniso-osmolarity-induced changes 
in the phosphorylation and activity of endogenous Erk-1 and 
Erk-2 in C6 glioma cells and an increase in [Ca2+]j, resulting 
from Ca2+ influx across the plasma membrane. Osmosensitiv-
ity of Erk-1 and Erk-2 activity was independent of extracel-
lular Ca2+ and PI3 kinase but sensitive to cAMP, pointing to 
a role of Ras/Raf in the pathway to Erk-1 and Erk-2. This 
contrasts the osmosignalling to Erk-1 and Erk-2 in primary 
astrocytes, which was shown to be dependent on influx of 
extracellular Ca2+ and PI3 kinase [12]. Thus, marked differ-
ences exist between osmosignalling in C6 glioma cells and 
primary astrocytes. 
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2. Materials and methods 
2.1. Materials 
Anti-Erk-1 and anti-Erk-2 antibodies were obtained from UBI 
(Lake Placid, NY, USA); anti-Raf-1 from Santa Cruz Biotechnology. 
Genistein and daidzein were purchased from Calbiochem-Novabio-
chem GmbH (Bad Soden, Germany), l-[6-[17p-3-methoxyestra-
l,3,5(10)-trien-17-yl]amino]hexyl-lii-pyrrole-2,5-dione (U73122), 1-
[6-[17p-3-methoxyestra-l,3,5(10)-trien-17-yl]amino]hexyl-17i-pyrrol-
idine-2,5-dione (U73343), 8-CPT-cAMP and isoproterenol were from 
Biomol Res. Lab. Inc. (Hamburg, Germany) and pertussis and chol-
era toxin from Research Biochemicals Incorporated (Natick, MA, 
USA). G56850 was a gift from Godecke AG (Freiburg, Germany), 
Pluronic F-127 and the acetoxymethylester of fura-2 were purchased 
from Molecular Probes Inc (Eugene, OR, USA). Cell culture media 
and fetal calf serum were from Gibco Life Technologies (Gaithers-
burg, MD, USA). Sodium orthovanadate, forskolin and isobutyl-
methylxanthine were obtained from Sigma (Munich, Germany). 
ATP was from Boehringer (Mannheim, Germany) and γ-[32Ρ]ΑΤΡ 
was from Amersham. (Braunschweig, Germany). All other chemicals 
were from Merck (Darmstadt, Germany). 
2.2. Cell culture and aniso-osmotic treatment 
C6 glioma cells (ATCC CCL107) were maintained in Dulbecco's 
modified Eagle's medium (DMEM), supplemented with 10% fetal calf 
serum (FCS) in a humidified atmosphere of 95% air, 5% C0 2 . When 
cells had reached 90% confluence, they were washed with Dulbecco's 
PBS and culture was continued in serum-free medium for an addi-
tional 24 h. Following 5 min preincubation with 100 μpiιοΐ/ΐ sodium 
vanadate aniso-osmolarity was achieved by dilution of the medium 
with the appropriate volume of NaCl-free medium (205 mosmol/1) or 
with medium of elevated NaCl content, thereby maintaining 100 
μpiιοΐ/ΐ vanadate. In the normo-osmotic control (305 mosmol/1), the 
same volume of normo-osmotic medium, containing 100 μpiιοΐ/ΐ vana-
date, was added. Normo-osmotic raffinose medium was prepared by 
substitution of 50 mmol/1 NaCl against 100 mmol/1 raffinose; hypo-
osmolarity was adjusted by removing 100 mmol/1 raffinose. Hyper-
osmotic raffinose medium was prepared by addition of 100 mmol/1 
raffinose to normo-osmotic medium. 
2.3. Detection of mobility-shifted Erk-1, Erk-2 and Raf-1 
At the end of the incubation period, medium was removed and cells 
were immediately lysed at 4°C using 50 mmol/1 Tris-HCl buffer (pH 
7.2) containing 150 mmol/1 NaCl, 40 mmol/1 NaF, 5 mmol/1 EDTA, 
5 mmol/1 EGTA, 1 mmol/1 vanadate, 0.5 mmol/1 phenylmethylsulfonyl 
fluoride (PMSF), 0.1% aprotinin, 1% Nonidet-P40, 0.1% sodium 
deoxycholate and 0.1% SDS. The homogenized lysates were centri-
fuged at 20000Xg at 4°C and the supernatant was added to an iden-
tical volume of gel loading buffer containing 200 mmol/1 dithiothreitol 
(DTT, pH 6.8). After heating to 95°C for 5 min, the proteins were 
subjected to gel electrophoresis (50 μg protein/lane, 9% gel). Follow-
ing electrophoresis, gels were equilibrated with transfer buffer (39 
mmol/1 glycine, 48 mmol/1 Tris-HCl, 0.03% SDS, 20% methanol). 
Proteins were transferred to nitrocellulose membranes using a semi-
dry transfer apparatus (Pharmacia, Freiburg, Germany). Blots were 
blocked in 5% bovine serum albumin containing TBST (20 mmol/1 
Tris-HCl pH 7.5, 150 mmol/1 NaCl, 0.1% Tween 20) and then incu-
bated overnight with l:50000-diluted antiserum against Erk-1, Erk-2 
or Raf-1. Following washing with TBST and incubation with horse-
radish peroxidase-coupled anti-rabbit IgG antibody diluted 1:10000 
at room temperature for 1 h, the blots were washed three times and 
developed using enhanced chemiluminescent detection (Amersham, 
Braunschweig, Germany). 
2.4. Immune complex kinase assay 
The assay was performed as described previously [20]. Briefly, ali-
quots of cell lysate containing 20 μg protein (lysis buffer: 1% Triton 
X-100, 150 mmol/1 NaCl, 10 mmol/1 Tris-HCl pH 7.4, 1 mmol/1 
EDTA, 1 mmol/1 EGTA, 20 mmol/1 NaF, 0.2 mmol/1 PMSF, 0.5% 
NP-40) were incubated with 1.5 μg of a monoclonal antibody against 
Erk-2 (class IgG 2a) for 2 h at 4°C. Immune complexes were collected 
using protein A-Sepharose 4B (Pharmacia), washed three times with 
lysis buffer and six times with kinase buffer (10 mmol/1 Tris-HCl pH 
7.4, 150 mmol/1 NaCl, 10 mmol/1 MgCl2, 0.5 mmol/1 DTT) and in-
cubated with 1 mg/ml myelin basic protein (MBP), 25 μιηοΐ/ΐ ATP 
and 5 μθί γ-[32Ρ]ΑΤΡ for 30 min at 37°C. The activity of Erk-2 was 
monitored by autoradiography after SDS polyacrylamide electrophor-
esis (12.5% gel). 
2.5. Ca2+ imaging at the single cell level 
Astrocytes were grown on coverslips in DMEM+10% FCS. Follow-
ing 24 h serum starvation sub-confluent cells were incubated with 
Krebs-Henseleit medium (KHB: 115 mmol/1 NaCl/25 mmol/1 
NaHC03/5.9 mmol/1 KC1/1.18 mmol/1 MgCl2/1.23 mmol/1 
NaH2P04/1.2 mmol/1 Na2S04/1.25 mmol/1 CaCl2), containing 5 
μηιοΐ/ΐ of the fluorescent Ca2+ chelator fura-2 acetomethoxyester 
and 0.02% pluronic F-127, for 30 min at 37°C and 5% C0 2 . For 
fluorescence recording, the coverslips were continuously superfused 
at a rate of 15 ml/min with KHB at 37°C, equilibrated with 0 2 / 
C0 2 (95/5, v/v), resulting in pH 7.4. Measurement of intracellular 
Ca2+ was performed as described [21], 
3. Results 
3.1. Activation of Erk-1 and Erk-2 and occurrence of 
mobility-shifted Raf-1 in response to aniso-osmotic 
challenge of C6 glioma cells 
Alterations in the phosphorylation of endogenous Erk-1 
and Erk-2 in C6 glioma cells in response to hypo-osmotic 
Fig. 1. Osmolarity dependence of Erk-1 and Erk-2 activity and Raf-1 phosphorylation in rat C6 glioma cells, determined by mobility shifts and 
immune-complex assay. Following 5 min pretreatment with 100 μpiιοΐ/ΐ vanadate, cells were treated with hypo-osmotic (205 mosmol/1), normo-
osmotic (305 mosmol/1) or hyper-osmotic (405 mosmol/1) medium for the time indicated, thereby maintaining 100 μpiιοΐ/ΐ vanadate. Representa-
tive results from four independent experiments are shown. The extract of total protein was analyzed by Western blot, using antibodies specifi-
cally raised against Erk-1, Erk-2 or Raf-1. The immune complex assay was performed with MBP, using an antibody raised against Erk-2. 
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Fig. 2. Effect of hypo-osmolarity and extracellular ATP on intracel-
lular free Ca2+ concentration [Ca2+]j in C6 glioma cells, measured 
with fura-2 on single cell level. Normo-osmotic (305 mosmol/1) 
superfusion medium was suddenly changed to hypo-osmolarity (205 
mosmol/1) as indicated. Representative traces from three experiments 
are shown in each case. A: Presence of 1.25 mmol/1 extracellular 
Ca2+. B: Ca2+-free conditions: iso-osmotic replacement of 1.25 
mmol/1 CaCl2 by NaCl and 5 mmol/1 EGTA, 2 min before and dur-
ing treatment of the cells. No desensitization of the signal was ob-
served after twice application of hypo-osmolarity in presence of ex-
tracellular Ca2+ (data not shown). C: 20 min pretreatment of the 
cells with 1 μpiιοΐ/ΐ U73122. Following addition of this PLC inhibi-
tor, the hypo-osmolarity-induced but not the ATP-induced [Ca2+]i 
signal was preserved. 
swelling or hyper-osmotic shrinkage of the cells were detected 
using the mobility shift assay. In order to amplify the phos-
phorylation signals, cells were preincubated with 100 μpiιοΐ/ΐ 
sodium vanadate, which was also present during aniso-osmot-
ic stimulation and in the normo-osmotic control. Reduction 
of medium osmolarity from 305 to 205 mosmol/1 induced a 
shift of Erk-1 and Erk-2 towards higher molecular masses 
within 3 min, which became maximal after 10 min and de-
clined within 120 min to the basal level (Fig. 1; » = 4). The 
mobility shifts observed under normo-osmotic conditions (305 
mosmol/1) reflect the basal phosphorylation state of Erk-1 and 
Erk-2 in C6 glioma cells. On the other hand phosphorylation 
of Erk-1 and Erk-2 was diminished under hyper-osmotic con-
ditions. The results obtained with the mobility shifts were 
confirmed by direct kinase activity measurements using 
MBP as substrate for Erk-2 (Fig. 1). In the absence of vana-
date only weak phosphorylation signals were found, which 
were inconsistent and difficult to pick up. Erk activation 
was not due to a change of sodium or chloride concentration 
in the medium as no effect on Erk-1 and Erk-2 was obtained 
when 50 mmol/1 NaCl was replaced by 100 mmol/1 raffinose, 
thereby maintaining normo-osmolarity. Further, decreased ac-
tivity of Erk-1 and Erk-2 was obtained when 100 mmol raffi-
nose were added to normo-osmotic medium, thereby adjusting 
hyper-osmolarity (data not shown). With some delay Erk ac-
tivation was accompanied by the occurrence of mobility-
shifted Raf-1 (Fig. 1) which represents some phosphorylated 
forms of the Raf-1 kinase. 
3.2. Elevation of [Ca2+Ji following hypo-osmotic exposure of 
C6 glioma cells 
Hypo-osmotic (205 mosmol/1) treatment of the C6 glioma 
cells increased cytosolic free Ca2+ from basal levels of 
84.2 ±6.1 nmol/1 to 203.9 ±29.4 nmol/1 (w = 3). The elevation 
in [Ca2+]i was maintained in a plateau-like manner as long as 
hypo-osmotic exposure was continued (Fig. 2A). In order to 
study the contribution of extracellular Ca2+ to the hypo-os-
molarity-induced [Ca2+]j response, extracellular Ca2+ was re-
moved and 0.5 mmol/1 EGTA was added 2 min before switch-
ing to hypo-osmotic medium. Under these conditions [Ca2+]i 
remained unaffected (Fig. 2B; n-3). Following hypo-osmotic 
stress, the [Ca2+]; increase was largely absent when extracel-
lular Ca2+ was depleted (Fig. 2B; n = 3). This suggests that the 
plateau may predominantly result from entry of extracellular 
Ca2+. When C6 glioma cells were preincubated with U73122, 
which is a potent inhibitor of both ΡΙΧβ and PLCy [22,12], 
the hypo-osmolarity-induced [Ca2+]; response was preserved 
(Fig. 2C). As for control, the ATP-triggered Ca2+ signal com-
pletely disappeared in the presence of the PLC inhibitor (Fig. 
2C) but remained unaffected in the presence of its inactive 
analog U73343 (n = 3; not shown). Like in astrocytes [12] 
the [Ca2+]i response to hypo-osmolarity was not affected by 
the presence of vanadate (100 μΜ; n-3, not shown). It is 
concluded that the hypo-osmolarity-induced changes in 
[Ca2+]; are independent of PLC action. 
3.3. Swelling-induced activation of Erk-1 and Erk-2 is 
independent of extracellular Ca2+ and requires 
cAMP-sensitive signalling steps 
During Ca2+-free conditions the osmosensitivity of Erk-1 
and Erk-2 activity was completely maintained (Fig. 3, lanes 
4-6; » = 4), pointing to a signalling pathway to Erk-1 and 
Erk-2 independent of extracellular Ca2+. Like the hypo-osmo-
larity-induced [Ca2+]; response (Fig. 2B), the activity states of 
Erk-1 and Erk-2 were preserved in the presence of the PLC 
inhibitor U73122 (Fig. 3, lanes 7-9; n-3), indicating no re-
quirement of PLC in triggering the osmosignalling to the 
MAP kinases. Application of G66850, a potent PKC inhibitor 
of broad specificity [23], did not abolish the activation of Erk-
1 and Erk-2 following hypo-osmotic exposure of the C6 glio-
ma cells (Fig. 3, lanes 10-12; n = 3). Wortmannin at a con-
centration of 100 nmol/1, sufficient to specifically inhibit PI3 
kinase in other cell types [24], was also without effect on the 
osmosensitivity of Erk-1 and Erk-2 (Fig. 3, lanes 13-15; 
n = 3). The same was observed in the presence of LY294002 
(n-3; not shown), another PI3 kinase inhibitor, which works 
in a mechanistically different manner from wortmannin [25]. 
When C6 glioma cells were pretreated with 8-CPT cAMP, 
the osmosensitivity of the MAP kinases was completely abol-
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Fig. 3. Inhibitor sensitivity of the osmolarity dependence of Erk-1 and Erk-2 activity in C6 glioma cells. Representatives of at least three inde-
pendent experiments are shown. Cells were pretreated with 100 μpiιοΐ/ΐ vanadate and aniso-osmolarity was adjusted without further pretreatment 
(controls) or after applying inhibitors as indicated. Conditions: control (lanes 1-3); EGTA: 5 mmol/1, 1 min (lanes 4-6); U73122: 10 μιηοΐ/ΐ, 
30 min (lanes 7-9); G56850: 1 umol/l, 20 min (lanes 10-12); wortmannin: 100 nmol/1, 20 min (lanes 13-15); 8-CPT cAMP: 0.5 mmol/1, 20 
min (lanes 16-18); forskolin (50 μΐϊΐοΐ/ΐ) and isobuthylmethylxanthine (IBMX, 100 μηιοΐ/ι) for 20 min (lanes 19-21); (—)isoproterenol: 5 μηιοΐ/ΐ, 
20 min (lanes 22-24). 
ished (Fig. 3, lanes 16-18; n-4). The same was true for other 
maneuvers to increase cellular cAMP levels: forskolin and 3-
isobutyl-1-methylxanthine, which act through activation of 
adenylylcyclase and inhibition of phosphodiesterase, respec-
tively (Fig. 3, lanes 19-21; M = 4) . Also activation of adeny-
lylcyclase-linked β-adrenoceptors by isoproterenol blocked the 
osmosensitive signal transduction pathway to the MAP ki-
nases (Fig. 3, lanes 22-24; n = 4). 
4. Discussion 
This study demonstrates that the phosphorylation and the 
activity of the endogenous MAP kinases Erk-1 and Erk-2 of 
C6 glioma cells increased with decreasing osmolarity and was 
associated with the occurrence of mobility-shifted Raf-1 (Fig. 
1). The hypo-osmolarity-induced increase in [Ca2+]i in C6 
glioma cells (Fig. 2A) resulted from an influx from the extra-
cellular space (Fig. 2B) and was independent of PLC action 
(Fig. 2C). The osmosignalling to Erk-1 and Erk-2 was inde-
pendent of extracellular Ca2+ as well as from PLC (Fig. 3A), 
tyrosine kinases, PKC and PI3 kinase (Fig. 3B) but was abol-
ished by elevated intracellular cAMP levels (Fig. 3C). Pertus-
sis or cholera toxin-sensitive G proteins as well as genistein-
sensitive tyrosine kinases are apparently not involved in the 
signalling steps upstream to Erk-1 and Erk-2 (not shown). 
The findings suggest a swelling-induced activation of MAP 
kinases via the Ras/Raf pathway. The occurrence of mobil-
ity-shifted Raf-1 following Erk activation may be due to in-
activating phosphorylation of Raf-1 by the MAP kinases 
within a feedback loop [26]. 
Due to similarities in RVD between C6 glioma cells and 
primary astrocytes [11,27-29], C6 glioma cells were frequently 
used as a model system for astrocytes to study volume regu-
latory osmolyte fluxes [30,9,11] and osmotic stress-induced 
alterations in gene expression [10]. Hypo-osmolarity-induced 
activation of Erk-1 and Erk-2 was recently also observed in 
primary rat astrocytes [12]. Similar to C6 glioma cells this 
pathway was blocked by elevation of intracellular cAMP, 
suggesting a role of the Ras/Raf pathway in hypo-osmotic-
induced signalling to Erk-1 and Erk-2 in both C6 glioma cells 
and astrocytes. However, upstream of Ras/Raf cell type-spe-
cific differences were found: in contrast to C6 glioma cells 
(this paper), in astrocytes the hypo-osmolarity-induced Erk 
activation was completely abolished in the absence of extra-
cellular Ca2+ and by PI3 kinase inhibition [12]. Moreover, the 
plateau-like [Ca2+]j increase following hypo-osmotic treatment 
of C6 cells (Fig. 2A) contrasts to the biphasic [Ca2+]; response 
observed in astrocytes, which also involves Ca2+ release from 
intracellular stores [12,13], however, both responses occurred 
independent from inhibition of PLC by U73122 (this paper, 
[12]). The absence of a [Ca2+]i response to hypo-osmolarity in 
C6 glioma reported earlier [28] may be due to the use of cell 
suspensions, which requires dissociation of the cells from their 
culture substrate and possible leads to altered cell function. 
The osmosignalling events in C6 glioma cells upstream of the 
Ras/Raf-MAP kinase pathway remain obscure. They appar-
ently do not involve PI3 kinase and Ca2+ as observed in 
primary astrocytes [12], G-proteins and tyrosine kinases as 
observed in hepatocytes [31] and hepatoma cells [32] or the 
action of PKC and PLC. 
The presence of vanadate, which among other things works 
as a protein tyrosine phosphatase inhibitor [33], was necessary 
to amplify the swelling-induced activation of Erk-1 and Erk-2 
in C6 glioma cells (this paper) but not in astrocytes [12]. Like-
wise vanadate was necessary in hepatoma cells [32] but not in 
hepatocytes [31] in order to pick up the swelling-induced Erk 
activation. Whether the differences in sensitivity of Erk-1/Erk-
2 are due to different levels of the constitutively expressed and 
Erk-specific MAP kinase phosphatase PYST2, which was 
cloned recently [34], remains to be established. Despite the 
presence of vanadate the swelling-induced Erk activation 
was transient in C6 glioma cells, which may reflect the induc-
tion of a MAP kinase phosphatase activity which overcomes 
the inhibitory potential of 100 μpiιοΐ/ΐ vanadate used in the 
present study. 
Apart from hepatocytes [31], hepatoma cells [32], astrocytes 
[12] and C6 glioma cells (this paper), hypo-osmolarity-induced 
stimulation of Erk-type MAP kinases is also observed in the 
human intestine 407 cell line [35], in RAW 264.7 mouse 
macrophages, skin fibroblasts, vascular endothelial cells (F. 
Schliess and D. Haussinger, unpublished work) and yeast 
[36], and thus seems to be a general feature, which is in line 
with the growth factor-like action of cell swelling in many 
aspects [1,4,5]. 
Hyper-osmotic stress was shown to activate Erks in Madin-
Darby canine kidney cells [37,38] while activation of both 
Erk-like MAP kinases and stress-activated protein kinases 
was found in rat 3Y1 fibroblasts, PC 12 cells [39] and ven-
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tricular rat myocytes [40]. In RAW 264.7 mouse macrophages 
p38, a MAP kinase which is related to the high osmolarity 
response gene (HOG1) of Saccharomyces cerevisiae [41] was 
activated in response to hyper-osmolar stress [42]. In contrast 
no activation of Erks was reported in RAW macrophages 
after hyper-osmotic treatment of the cells [42]. In primary 
astrocytes (R. Sinning and D. Haussinger, unpublished result) 
and C6 glioma cells (this paper) hyper-osmotic treatment led 
to a decrease of Erk-1 and Erk-2 activity below basal levels 
(Fig. 1), suggesting the induction within minutes of a phos-
phatase activity, whose identity remains to be clarified. 
Taken together, astrocytes as well as C6 glioma cells re-
sponded with changes in [Ca2+]; and Erk activity to aniso-
osmolarity but cell type-specific differences with respect to 
osmosensitivity and upstream signalling steps are obvious. 
Thus, extrapolation of findings obtained in C6 glioma cells 
to the situation in primary astrocytes may be problematic. 
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